Year: 2025

DENVER, Oct. 23, 2025 (GLOBE NEWSWIRE) — Pure Cycle Corporation (NASDAQ: PCYO) announced today that Mark W. Harding, President and CEO of Pure Cycle, will participate in the ThinkEquity Conference on October 30, 2025, at the Mandarin Oriental in New York City. “I am excited to present at the ThinkEquity conference and discuss the continued successes of Pure Cycle. Pure Cycle has seen tremendous growth not only at our master planned community at Sky Ranch, but also in our continued expansion of our regional water system which services the Sky Ranch community and other areas throughout our service area,” commented Mr. Harding. The ThinkEquity Conference convenes institutional investors, analysts, and emerging growth companies for a day of presentations and one-on-one meetings, providing a valuable platform to share business updates...

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) — via InvestorWire — Nightfood Holdings inc. (NGTF) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “AI, Robotics Power Expansion and Uplisting Momentum Across Emerging Markets,” please visit: https://nnw.fm/7fquq The convergence of artificial intelligence (AI) and robotics is reshaping global industries, from logistics and manufacturing to hospitality and hotel management. As demand for automation rises, small-cap companies are accelerating growth through targeted acquisitions...

WEST DES MOINES, Iowa, Oct. 23, 2025 (GLOBE NEWSWIRE) — West Bancorporation, Inc. (Nasdaq: WTBA; the “Company”), parent company of West Bank, today reported third quarter 2025 net income of $9.3 million, or $0.55 per diluted common share, compared to second quarter 2025 net income of $8.0 million, or $0.47 per diluted common share, and third quarter 2024 net income of $6.0 million, or $0.35 per diluted common share. For the first nine months of 2025, net income was $25.1 million, or $1.48 per diluted common share, compared to $17.0 million, or $1.00 per diluted common share, for the first nine months of 2024. On October 22, 2025, the Company’s Board of Directors declared a regular quarterly dividend of $0.25 per common share. The dividend is payable on November 19, 2025, to stockholders of record on November 5, 2025. David Nelson,...

A presentation will be held via Teams 24/10 at 08.15 am CET, where the CEO presents the report. You can participate by register on the link below: Registration Form For further information about Nilörn, please contact: Krister Magnusson, CEO Tel: +46704-852 114. E-mail: krister.magnusson@nilorn.com General about Nilörn Group Nilörn Group is a global company, founded in the 1970s, with expertise in how to add value to brands through branding and design in the form of labels, packaging and accessories, primarily to customers in the fashion and clothing industry. Nilörn Group offers complete, creative and tailor-made concepts in branding, design, product development and logistical solutions. The Group operates through its own companies in Sweden, Denmark, the UK, Germany, Belgium, Portugal, Hong Kong, India, Turkey, China, Bangladesh, Italy,...

SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced presentation of a poster entitled “Targeting HPV E6/E7 Upregulation of the Transmembrane Receptor Tyrosine Kinase ROR2 with the ADC Ozuriftamab Vedotin in Patients with Advanced HPV+ Oropharyngeal Squamous Cell Carcinoma” which details clinical data from its investigational antibody-drug conjugate (ADC), ozuriftamab vedotin (Oz-V), at the International Papillomavirus Society (IPVS) Conference, taking place October 23–26, 2025, in Bangkok, Thailand. The poster will provide a deeper molecular review of Oz-V, CAB-ROR2-ADC, a more detailed mechanistic discussion regarding the relationship...

Beta launch introduces deterministic CTV measurement to global markets, connecting premium streaming exposure to qualified visits, leads, and sales NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) — Teads (NASDAQ: TEAD), the omnichannel outcomes platform for the open internet, today announced the beta launch of CTV Performance, an innovative performance solution that tracks exposure to action, bringing accountability to connected TV campaigns for the first time outside of the US. CTV Performance enables advertisers to move beyond traditional CTV metrics like impressions and completion rates, offering a new layer of insight: the ability to track site visits, leads, and sales directly tied to CTV exposure. Built to complement Teads’ broader omnichannel offering, this solution allows brands to use premium streaming environments for awareness...

FLORHAM PARK, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced its participation in the American College of Gastroenterology’s (ACG) 2025 Annual Scientific Meeting, being held October 24-29 in Phoenix, Arizona. Phathom will showcase its growing leadership in GI through multiple engagements with the medical and scientific community, including a product theater presentation highlighting VOQUEZNA® (vonoprazan) tablets as an approved treatment for Gastroesophageal Reflux Disease (GERD) and a prominent presence on the exhibit floor. “We are excited to build on the growing momentum for VOQUEZNA in the treatment of GERD by connecting with the GI community at ACG,”...

— Findings Presented at AMCP Nexus 2025 Annual Meeting — BRISBANE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) — Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced real-world evidence evaluating the clinical effectiveness and economic benefits of EXPAREL® (bupivacaine liposome injectable suspension) will be presented at the AMCP Nexus 2025 Annual Meeting taking place October 27–30 in National Harbor, Maryland. One presentation includes new real-world evidence from the company’s Innovations in Genicular Outcomes Registry, or IGOR, a first-of-its-kind multicenter, prospective, longitudinal observational registry. “Pacira continues to advance understanding of postsurgical pain management and the potential to...